Literature DB >> 27599851

Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil.

Jailton Azevedo1, Eder Silva Dos Anjos1, Soraia M Cordeiro2, Milena S Dos Santos3, Eliane C Escobar1, Paulo R Lobo1, Maria da Gloria Carvalho4, Mitermayer G Reis1, Joice N Reis1,2, Leila C Campos1.   

Abstract

In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Brazilian childhood vaccination programme. Concerns have been raised that non-vaccine serotypes could increase in prevalence and reduce the benefits of vaccination; therefore, we examined non-PCV10 isolates recovered from meningitis during pre- (January 2008-May 2010) and post-vaccine (June 2010-December 2012) periods. Surveillance for pneumococcal meningitis was established at the Reference Hospital of Infectious Diseases in Salvador, Brazil. Serotypes were determined by multiplex PCR and/or Quellung reaction. Antimicrobial susceptibility testing was conducted by E-test and broth microdilution. Genotyping used PFGE and multi-locus sequence typing. A total of 148 cases of meningitis were identified from January 2008 to December 2012, 77 (52 %) of which were due to non-PCV10 isolates, with 50 (52.1 %) from pre-vaccine and 27 (52 %) from post-vaccine periods. In the post-vaccine period, the non-PCV10 serotypes 12F (n=6; 22.2 %), 10A (n=3; 11.1 %), 15B (n=2; 7.4 %) and 18B (n=2; 7.4 %) were the most prevalent. Forty-three isolates (55.8 %) were non-susceptible to one or more antibiotics. Non-susceptibility to penicillin was observed among serotypes 19A (three isolates), 9N (one isolate) and 12F (one isolate). PFGE and multi-locus sequence typing results demonstrated a wide genetic diversity among the isolates. During the early period following PCV10 introduction, no obvious emergence of a particular serotype was evident among non-PCV10 strains. This study underscores the importance of monitoring any changes among non-PCV10 cases after the introduction of PCV10.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27599851     DOI: 10.1099/jmm.0.000346

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

1.  A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13.

Authors:  Brendan W Wren; Jeremy S Brown; Mark Reglinski; Giuseppe Ercoli; Charlie Plumptre; Emily Kay; Fernanda C Petersen; James C Paton
Journal:  NPJ Vaccines       Date:  2018-10-31       Impact factor: 7.344

2.  Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil.

Authors:  Ana Paula Cassiolato; Samanta Cristine Grassi Almeida; Ana Lúcia Andrade; Ruth Minamisava; Maria Cristina de Cunto Brandileone
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

3.  Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany.

Authors:  Stephanie Perniciaro; Matthias Imöhl; Christina Fitzner; Mark van der Linden
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

4.  Synthesis and delivery of Streptococcus pneumoniae capsular polysaccharides by recombinant attenuated Salmonella vaccines.

Authors:  Huali Su; Qing Liu; Xiaoping Bian; Shifeng Wang; Roy Curtiss; Qingke Kong
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

5.  Effect of Vaccination on Pneumococci Isolated from the Nasopharynx of Healthy Children and the Middle Ear of Children with Otitis Media in Iceland.

Authors:  Sigríður J Quirk; Gunnsteinn Haraldsson; Helga Erlendsdóttir; Martha Á Hjálmarsdóttir; Andries J van Tonder; Birgir Hrafnkelsson; Samuel Sigurdsson; Stephen D Bentley; Ásgeir Haraldsson; Angela B Brueggemann; Karl G Kristinsson
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

6.  Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.

Authors:  Adriana Guzman-Holst; Eliana de Barros; Pilar Rubio; Rodrigo DeAntonio; Otavio Cintra; Ariane Abreu
Journal:  Hum Vaccin Immunother       Date:  2021-03-18       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.